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Abstract  Inﬂammatory  bowel  disease  (IBD)  is  a  chronic  idiopathic  inﬂammatory  disease  of
the gastrointestinal  (GI)  tract.  In  the  past  decade  a  shift  in  the  treatment  paradigm  of  IBD  has
ensued.  The  availability  of  drugs  capable  of  inducing  mucosal  healing,  combined  with  the  recog-
nition that  IBD  is  not  an  intermittent  disease,  but  rather  a  progressive  one  causing  bowel  damage
and disability,  led  us  to  a  more  stringent  strategy.  Tailored  therapy  with  more  aggressive  treat-
ment in  high-risk  patients,  treating  beyond  symptoms,  intervening  early  before  damage  occurs,
optimizing  therapeutic  regimens,  and  actively  pursuing  sustained  remission  and  sustained  con-
trol of  inﬂammation  are  strategies  that  are  slowly  being  incorporated  in  our  clinical  practice.
Furthermore,  new  drugs  targeting  different  immunological  pathways,  such  as  vedolizumab,
have recently  been  approved  and  therefore  more  therapeutic  resources  for  patients  failing
anti-tumour  necrosis  factor  alpha  (anti-TNF)  agents  will  be  available.
The future  years  look  promising  for  IBD.  Hopefully  the  new  trends  in  IBD  management,  com-
bined with  new  drugs,  will  make  possible  to  change  the  course  of  disease  and  provide  better
therapy  and  quality  of  life  for  patients  suffering  from  this  disabling  disease.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.U.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
PALAVRAS  CHAVE
Colite  Ulcerosa;
Doenc¸a  de  Crohn;
Doenc¸a Inﬂamatória
Novas  Estratégias  Terapêuticas  na  Doenc¸a Inﬂamatória  do  Intestino
Resumo  A  doenc¸a  inﬂamatória  intestinal  (DII)  é  uma  doenc¸a  idiopática  crónica  e  incapacitante
do trato  gastrointestinal.  Na  última  década  tem-se  assistido  a  uma  modiﬁcac¸ão  nas  estratégiasIntestinal;
Terapia  Molecular
de abordagem  e  tratamento  do  doente  com  DII.  O  desenvolvimento  de  fármacos  potentes  com
capacidade  de  induzir  a  cicatrizac¸ão  da  mucosa,  aliado  ao  reconhecimento  do  carácter  progres-
sivo da  doenc¸a,  com  dano  intestinal  irreversível  e  compromisso  da  qualidade  de  vida,  conduziu
is  rigorosas.  Tem-se  assistido  à  incorporac¸ão  de  novas  estratégias  na
mo  terapêutica  individualizada  mais  agressiva  em  doentes  com  mau
ente,  uso  de  outros  objetivos  terapêuticos  para  além  da  remissãoDirigida;
Monitorizac¸ão de
Medicamentos
à adoc¸ão  de  estratégias  ma
prática clínica  atual,  tais  co
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sintomática,  intervenc¸ão  precoce  para  evitar  o  desenvolvimento  de  dano  intestinal  irrever-
sível, optimizac¸ão  da  terapêutica  com  objetivo  de  alcanc¸ar  a  remissão  sustentada  e  o  controlo
da inﬂamac¸ão.  Adicionalmente,  a  aprovac¸ão  de  novos  fármacos  com  ac¸ão  em  vias  imunológi-
cas alternativas,  como  o  vedolizumab,  permitirá  alargar  o  espetro  terapêutico  no  doente  não
respondedor  a  agentes  anti-factor  de  necrose  tumoral  alfa.
O futuro  parece  promissor  na  área  da  DII.  É  expectável  que  as  novas  estratégias  de  abor-
dagem do  doente  com  DII,  aliadas  ao  desenvolvimento  de  novos  fármacos,  permitam  alterar  o
curso natural  da  doenc¸a,  evitando  o  dano  intestinal  irreversível  e  possibilitando  a  melhoria  da
qualidade de  vida  destes  doentes.
©  2015  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.
Este é  um  artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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d. Introduction
n  the  past  years,  inﬂammatory  bowel  disease  (IBD)  has
itnessed  major  advances  both  at  the  fundamental  and  clin-
cal  levels.  Key  discoveries  in  disease’s  pathogenesis  led  to
he  development  and  reﬁnement  of  therapeutic  strategies
aving  the  way  for  a  new  era  in  targeted  drug  development.1
Therapeutic  management  in  IBD  has  also  suffered  a  major
hift  in  the  past  years.  The  traditional  paradigm  of  grad-
ally  introducing  the  least  toxic  but  less  powerful  drugs
nd  repeated  courses  of  steroids  has  progressively  moved
o  favour  the  early  introduction  of  immunomodulation  and
ost  recently  biologic  therapy,  in  order  to  modify  the  natu-
al  history  of  disease.2
The  discovery  and  introduction  of  anti-TNF  agents  have
onstituted  a  major  breakthrough  for  patients  and  clini-
ians.  These  novel  therapies  offer  the  ability  to  induce
nd  maintain  remission,  heal  the  mucosa,  and  reduce  surg-
ries  and  hospitalizations.3 However,  many  patients  will
till  be  refractory  to  treatment  or  loose  response  over
ime.  Therefore,  therapeutic  drug  monitoring,  as  a  way  of
ptimizing  anti-TNF  use,  has  been  an  area  of  intensive
esearch.  Furthermore,  new  drugs  are  expected  to  hit  the
linic.  Vedolizumab,  an  anti-integrin,  is  eagerly  awaited  for
atients  who  have  failed  anti-TNF  and  it  has  shown  to
e  able  to  induce  and  maintain  remission  in  patients  with
rohn’s  disease  (CD)  and  ulcerative  colitis  (UC).
We  are  increasingly  using  prognostic  and  predictive
actors  at  diagnosis  and  during  follow-up  to  guide  our  ther-
peutic  decisions.  We  now  recognize  that  in  order  to  block
isease  progression,  it  is  crucial  to  intervene  early  before
amage  occurs.
In this  review  we  will  brieﬂy  discuss  new  therapies  in
BD,  and  we  will  focus  on  new  trends  that  are  emerging  in
he  treatment  of  IBD  patients,  with  the  goal  of  optimizing
urrent  therapeutic  strategies  and  blocking  disease  progres-
ion.
. Prognostication in IBDBD  is  a  heterogeneous  condition  with  a  highly  vari-
ble  clinical  course,  with  some  patients  following  a  mild
ourse  while  others  experience  early  and  aggressive  dis-
ase  progression.4--6 Therapeutic  strategies  in  IBD  result
m
d
e
srom  a  delicate  and  difﬁcult  balance  between  beneﬁts
nd  risks  of  more  aggressive  therapies.  Early  treatment
ith  immunomodulators  and/or  anti-TNF  is  expected  to
hange  the  natural  history  of  disease,  especially  for  CD,
ut  with  the  risk  of  overtreating  some  patients  with  mild-
oderate  disease  who  would  not  need  such  intensive
herapy.  Therefore,  the  possibility  of  patient  proﬁling  using
rognostic  factors  at  diagnosis  (including  clinical,  laboratory
nd  imaging  criteria)  for  the  selection  of  the  best  suited  can-
idates  for  early  aggressive  therapies  is  of  main  importance
Tables  1  and  2).7,8
Several  deﬁnitions  of  poor  prognosis  in  CD  have  been  sug-
ested.  Disabling  CD  was  arbitrarily  deﬁned  by  Beaugerie  et
l9 in  2006  by  the  presence  of  at  least  one  of  the  follow-
ng  criteria  in  the  5-year  period  after  diagnosis:  More  than
wo  steroid  courses  and/or  steroid  dependency;  further  hos-
italization  after  diagnosis  for  ﬂare  up  or  complications  of
he  disease;  presence  of  disabling  chronic  symptoms;  need
or  immunosuppressive  therapy;  and  intestinal  resection  or
urgery  for  perianal  disease.  In  a  recent  meta-analysis8
ncluding  1961  patients,9--11 the  demographic  and  clinical
haracteristics  associated  with  signiﬁcantly  higher  risk  of
eveloping  disabling  disease  at  ﬁve  years  after  initial  diag-
osis  were:  young  age  (<40  years)  at  diagnosis,  initial
equirement  of  steroids  for  treating  the  ﬁrst  ﬂare  and  peri-
nal  disease.8
In  2012,  Zallot  and  Peyrin-Biroulet12 suggested  a  dif-
erent  deﬁnition  for  complicated  IBD.  Complicated  CD
as  deﬁned  as  the  presence  of  bowel  damage  (stric-
ure,  abscess  and/or  ﬁstula)  and/or  the  requirement  for
urgery  and/or  the  presence  of  extra-intestinal  manifes-
ations.  Clinical  factors  associated  with  complicated  CD
nclude  young  age  at  diagnosis,  small  bowel  disease  (ileal
nd/or  ileocolonic),  upper  gastrointestinal  extent,  stric-
uring  or  penetrating  behaviour,  perianal  disease,  severe
ndoscopic  lesions  (deep  ulcerations)  at  index  colonoscopy
nd  smoking.12--16
Complicated  UC  was  deﬁned  as  the  development  of  colon
ancer  and/or  the  need  for  surgery  (colectomy)  and/or  the
resence  of  extra-intestinal  manifestations.12 Clinical  pre-
ictors  for  complicated  UC  include  young  age  at  diagnosis,
ale  gender,  extensive  colitis,  severe  disease  activity  at
iagnosis,  high  histological  inﬂammation  score,  the  pres-
nce  of  primary  sclerosing  cholangitis,  steroid  use  and
teroid  resistance.4,12,13,17--21
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Table  1  Clinical,  demographic  and  endoscopic  prognostic
predictors  in  Crohn’s  disease  (CD)  and  the  associated  impact
on disease  course.
Prognostic  factor  Impact  on  disease  course
Crohn’s  disease
Young  age  (<40  years)
at  diagnosis
•  Disabling  CD9,11,13
•  Complicated  CD  (surgery
included)12,13
•  Disease  recurrence13
Stricturing  behaviour
(B2)
•  Complicated  CD  (surgery
included)12,13
•  Severe  CD10
•  Disease  recurrence13
Penetrating
behaviour  (B3)
•  Complicated  CD12
Ileal  disease  (L1)  •  Complicated  CD  (including
surgery  and  disease  behaviour
progression)12,13,15,16
Ileocolonic  disease
(L3)
•  Disabling  CD10
•  Surgery13
Upper  GI  extent  (L4)  •  Complicated  CD  (surgery
included)12,13
Perianal  disease  •  Disabling  CD9--11
•  Complicated  CD12,15
Smoking  •  Complicated  CD12,15
•  Higher  recurrence  rate
(surgical  or  non-surgical)13,15
•  More  frequent  perianal
disease16
Weight  loss  >  5  kg  at
diagnosis
•  Severe  CD10
High  number  of  ﬂares
per  year
•  Progression  to  penetrating
behavior  and  development  of
perianal  disease16
Disease  duration  >  10
years
•  Complicated  CD15
Severe  endoscopic
lesions  (deep
ulcerations)  at
index  colonoscopy
•  Increased  rate  of  penetrating
complications  and  surgery14
Requirement  of
steroids  for
treating  the  ﬁrst
•  Disabling  CD9--11
Table  2  Clinical,  demographic  and  endoscopic  prognos-
tic predictors  in  ulcerative  colitis  (UC)  and  the  associated
impact on  disease  course.
Prognostic  factor  Impact  on  disease  course
Ulcerative  colitis
Young  age  at  diagnosis  •  Complicated  UC  (including
colectomy)12
Male  gender  •  Colectomy20,21
Extensive  colitis  •  Complicated  UC  (including
colectomy)4,12,13
Severe  disease  activity
at  diagnosis
•  Colectomy20
High  histological
inﬂammation  score
•  Colectomy19
Disease  duration  >  10
years
•  Colectomy20
Steroid  use  •  Colectomy19
Steroid  resistance  •  Colectomy20
Primary  sclerosing •  Complicated  UC  (colorectal
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suffering  from  IBD  in  different  areas  or  health  domains.29
In  the  years  to  come,  it  is  likely  that  predictors  of  bowelﬂare
Besides  clinical  characteristics,  various  immunologic  and
genetic  markers  have  been  associated  with  a  worse  dis-
ease  course.  The  presence  of  antibodies  to  Saccharomyces
cerevisiae  (ASCA),  to  Escherichia  coli  outer-membrane  porin
C  (OmpC),  to  CD-related  bacterial  sequence  I2,  and  to
the  CBir1  ﬂagellin  has  been  linked  to  early  CD  onset,
stricturing  and  penetrating  behaviour,  and  need  for  early
small  bowel  surgery.22,23 In  the  genetic  ﬁeld,  the  IBD  CHIP
project24 concluded  that  carriage  of  some  NOD2  variants
was  the  most  important  genetic  factor,  being  an  inde-
pendent  predictive  factor  for  ileal  CD  disease,  stenosing
and  penetrating  behaviours  and  need  for  surgery.  Other
genetic  markers  have  been  studied,  including  PRDM1  vari-
ants,  IL23R,  JAK2  and  TNFS15  which  also  appear  to  be
d
i
tcholangitis cancer)
ssociated  with  disabling  CD.7 However,  so  far,  there  is
nsufﬁcient  data  to  support  the  recommendation  to  use  anti-
ody  or  genetic  testing  in  clinical  practice  to  predict  IBD
ourse.25,26
.  New endpoints in IBD
n  CD,  subclinical  inﬂammation  often  persists  and  there  is
 progressive  evolution  to  structural  and  irreversible  bowel
amage,  which  frequently  requires  surgical  intervention.27
urrent  clinical  and  endoscopic  scores  only  measure  disease
ctivity  at  a  speciﬁc  time.  The  recently  published  Lémann
ndex  (Crohn’s  disease  digestive  tract  damage  score)  is  the
rst  tool  that  aims  to  measure  the  cumulative  structural
owel  damage,  including  strictures,  penetrating  lesions
abscesses  and  ﬁstulae),  and  surgical  resection.  This  evalua-
ion  includes  damage  location,  extent,  severity,  progression
nd  reversibility  (measured  by  imaging  techniques  and  the
eed  of  resection).27 In  each  organ  (upper  GI  tract,  small
owel,  colon/rectum  and  anus)  the  score  ranges  from  0.0
absence  of  damage)  to  10.0  (complete  resection).27 As
xpected,  the  median  Lémann  Index  increases  with  disease
uration.  There  are  numerous  future  potential  applications
or  this  index,  including  the  assessment  of  disease  pro-
ression  and  patients’  heterogeneity,  the  identiﬁcation  of
arameters  at  diagnosis  associated  with  a  high  risk  of  rapid
rogression,  and  the  impact  of  therapy  strategies  on  long-
erm  outcomes.27,28
Another  emerging  endpoint  is  disability,  as  an  objective
ay  of  measuring  the  impairments,  activity  limitations,  and
articipation  restrictions  that  are  experienced  by  patientsamage  and  disability  will  be  identiﬁed,  as  well  as  the
mpact  of  new  drugs  and  therapeutic  strategies  in  preventing
hem.
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. New therapeutic strategies -- tight control
onitoring and  the ‘‘treat-to-target’’ strategy
he  traditional  symptom-oriented  management  has  shown
ot  to  improve  long-term  outcomes  in  IBD.7 Therefore  a
ore  proactive  attitude  is  emerging  in  IBD,  similar  to  other
hronic  diseases.7
The  ‘‘treat-to-target’’  strategy  is  based  on  frequent
ssessment  of  disease  activity,  using  objective  markers  of
nﬂammation  and  subsequently  adjusting  therapy  accord-
ngly  to  reach  the  pre-established  target.7,28 The  ultimate
bjective  of  this  approach  is  to  modify  the  natural  course
f  the  disease.28 The  ideal  target  to  achieve  in  IBD  is  still
 matter  of  debate  and  likely  to  evolve.  So  far,  mucosal
ealing  (MH)  seems  to  be  the  best  established  therapeutic
ndpoint  both  in  UC  and  CD.30 The  deﬁnition  of  MH  used  in
ost  clinical  trials  is  the  ‘‘complete  absence  of  all  inﬂam-
atory  and  ulcerative  lesions’’.30,31 Several  clinical  trials
nd  population-based  studies  have  demonstrated  that  MH
chievement  is  associated  with  better  outcomes,  such  as
 lower  incidence  of  disease  relapse,  hospitalization  and
urgery.30,32--35
Due  to  the  invasive  nature  and  cost  of  endoscopy,  sev-
ral  other  treatment  goals  have  emerged,  such  as  the  use
f  cross-sectional  imaging  and  inﬂammation  biomarkers.36
lthough  new  endoscopic  and  therapeutic  techniques,  as
eep  enteroscopy,  have  a  speciﬁc  role  in  diagnosis  and
reatment  in  IBD,  magnetic  resonance  enterography  (MRE),
omputed  tomography  (CT)  and  ultrasound  (US)  may  be
lternatives  to  ileocolonoscopy.37 They  have  the  advan-
ages  of  being  less  invasive,  able  to  assess  the  small  bowel
nd  providing  information  about  the  transmural  nature  of
nﬂammation.36 CT  has  a  similar  accuracy  to  MRE  for  assess-
ng  disease  activity  in  CD,  but  the  risk  of  radiation  exposure
imits  its  use  as  a  monitoring  tool.36 Rimola  et  al38 sug-
ested  and  validated  a  Magnetic  Resonance  Index  of  Activity
MaRIA)  score  to  quantify  CD  activity  based  on  MRI  ﬁndings
n  each  ileocolonic  segment,  and  found  a  strong  correlation
ith  CDEIS  (Crohn’s  Disease  Endoscopic  Index  of  Severity).
n  a  systematic  review  by  Panes  et  al39,  including  16  studies
ith  a  total  of  1629  segments  assessed,  the  overall  sensi-
ivity  and  speciﬁcity  of  MRE  for  the  assessment  of  disease
ctivity  was  80%  and  89%,  respectively.  However,  the  accu-
acy  of  MRI  to  monitor  therapeutic  responses  has  not  yet
een  fully  ascertained.  In  a  recent  multicentre  prospective
tudy  with  48  patients  receiving  corticosteroids  or  anti-
NF,  the  disease  activity  was  assessed  before  and  after
reatment  using  MRE  (MaRIA  score)  and  ileocolonoscopy
CDEIS).  The  authors  found  a  signiﬁcant  correlation  between
maging  activity  index  and  CDEIS  scores,  with  MRE  determin-
ng  ulcer  healing  with  90%  accuracy.40
Non-invasive  biomarkers  of  intestinal  and  systemic
nﬂammation  may  represent  an  attractive  alternative
or  evaluating  disease  activity,  independently  of  disease
ocation.  The  most  broadly  used  and  extensively  stud-
ed  biomarkers  are  faecal  calprotectin  (FC)  and  serum
-reactive  protein  (CRP).36 There  is  a  correlation  between
hese  markers  concentration  and  endoscopic  lesions,  risk
f  relapse,  risk  of  complications  and  response  to  therapy.41
levated  biomarker  levels  are  associated  with  endo-
copic  and  histologic  bowel  inﬂammation.  In  general,  this
a
ﬁ
m
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orrelation  is  higher  when  using  faecal  biomarkers,  such
s  calprotectin.41 Nonetheless,  in  CD  patients  with  small
owel  involvement,  FC  seems  to  have  a  weaker  correlation
ith  endoscopic  activity.  In  such  cases,  CRP  levels  may
etter  reﬂect  the  transmural  inﬂammatory  process.36
he  association  between  non-invasive  biomarkers  levels
nd  intestinal  inﬂammation  is  not  always  accurate.  Up
o  one-third  of  patients  with  intestinal  inﬂammation  may
ave  normal  CRP  levels.42 However,  in  CD  patients  who
ave  a  raised  CRP  concentration  at  baseline,  changes  in
RP  levels  may  provide  useful  information  in  monitoring
esponse  to  treatment.7 Jürgens  et  al43 showed  that  in  CD
atients  treated  with  inﬂiximab,  early  normalization  of
RP  levels  correlated  with  sustained  long-term  response  to
herapy,  while  a persisting  increase  in  CRP  under  therapy
as  associated  with  a  high  likelihood  of  relapse.  Biomarkers
ave  been  studied  less  in  the  postoperative  setting.  The
occer  study  was  a  prospective  study  aiming  at  identifying
he  best  strategy  for  prevention  of  post-operative  CD.  As
 part  of  this  study  several  biomarkers  were  measured.  No
orrelation  between  increased  levels  of  CRP  and  disease
ecurrence  was  observed.44 Whereas,  following  surgery,
evels  of  FC  >100  g/g  indicated  endoscopic  recurrence
ith  89%  sensitivity  and  58%  speciﬁcity,  and  a  negative
redictive  value  of  91%.45
CRP  and  faecal  calprotectin  may  be  best  used  as  screen-
ng  tool  to  decide  the  ideal  timing  for  endoscopic  or
ross-sectional  imaging  reassessment.36 A recent  meta-
tudy  analysing  data  from  six  studies  (551  CD  patients)  found
hat  in  patients  with  symptoms  (CDAI  >  220),  CRP  ≤  5  mg/l
r  calprotectin  ≤  200  g/g  predicted  a  CDEIS  ≤  6  with  a
ensitivity  and  speciﬁcity  of  83%  and  71%,  respectively.46
herefore  with  the  use  of  appropriate  threshold  levels,
hese  biomarkers  could  help  to  make  decisions  about  the
deal  timing  of  endoscopy.41
Still,  the  reliability  of  these  biomarkers  to  predict  MH
s  not  fully  established.  Depending  on  the  calprotectin
oncentration  threshold  used,  its  sensitivity  and  speciﬁcity
n  predicting  absence  of  MH  were  70--100%  and  44--100%,
espectively.36 Recently,  D’Haens  et  al47 suggested  a  fae-
al  calprotectin  cut-off  value  of  250  g/g  levels  above  this
oncentration  predicted  large  ulcers  in  CD  (sensitivity  60%,
peciﬁcity  80%)  and  active  mucosal  disease  activity  (Mayo
0)  in  UC  (sensitivity  71%,  speciﬁcity  100%).  In  CD,  a  concen-
ration  <250  g/g  predicted  MH  (CDEIS  <3)  with  a  sensitivity
f  94%  and  a  speciﬁcity  of  62%.47 In  a  subanalysis  of  the  STORI
ohort  the  combination  of  faecal  calprotectin  (at  a  thresh-
ld  of  250  g/g)  and  CRP  (at  a  threshold  of  5  mg/l)  has  shown
o  improve  the  ability  to  predict  mucosal  healing  (sensitivity
0%,  speciﬁcity  70%).48
There  are  some  issues  that  need  to  be  deﬁned,  namely
he  optimal  time  frame  for  assessment  of  treatment  goals
n  a  ‘‘treat-to-target’’  strategy.  Using  MH  as  the  target,
ecent  trials  in  CD  found  that  in  patients  under  treatment
ith  immunosuppressives,  anti-TNF  or  a  combination  of
oth,  the  time  frame  for  achieving  MH  ranged  from  10  to
6  weeks.49--52 Allen  and  Peyrin-Biroulet28 suggested  that,
ndependently  of  the  method  used  (endoscopy,  MRE,  CRP
nd/or  faecal  calprotectin),  the  treatment  goal  should  be
rst  assessed  at  3--6  months  after  introduction  of  disease-
odifying  agents.  Bouguen  et  al7 proposed  that,  in  CD
atients  at  high  risk  for  disease-related  progression  or
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iNew  trends  in  inﬂammatory  bowel  disease  
complications,  MH  should  be  assessed  every  6  months  until
the  disappearance  of  ulceration  and  every  1--2  years  there-
after.
Another  controversy  issue  in  this  ‘‘treat-to-target’’  strat-
egy  is  the  management  of  insufﬁciently  healed  patients.36 It
is  not  yet  clear  whether  patients  in  clinical  remission  and
with  residual  mucosal  inﬂammation  have  a  worse  prognosis
than  patients  with  complete  MH.7
The  minimal  degree  of  mucosal  improvement  required
to  alter  outcomes  is  not  yet  known.  Ferrante  et  al53,  in  a
post  hoc  analysis  of  the  SONIC  trial  data,  showed  that  a
decrease  of  at  least  50%  in  CDEIS  from  baseline  to  week
26  (endoscopic  response)  was  associated  with  steroid-free
remission  at  week  50,  with  a  similar  speciﬁcity  and  sensi-
bility  to  mucosal  healing  (absence  of  ulcers).  The  impact  of
this  ﬁnding  on  long-term  outcomes  needs  to  be  clariﬁed.
5. New drugs in IBD
An  important  step  in  the  pathogenesis  of  IBD  involves  the
migration  of  leukocytes  into  the  gut.  The  recruitment  of  T-
cells  and  other  inﬂammatory  cells  to  the  intestinal  mucosa
leads  to  pro-inﬂammatory  cytokine  production,  affecting
the  endothelial  barrier  and  inducing  cell  apoptosis.54 Inte-
grin  antagonists  are  anti-adhesion  molecules  which  block
the  interaction  between  inﬂammatory  and  endothelial  cells,
thereby  disrupting  trafﬁcking  of  T-lymphocytes  into  the
inﬂamed  gut.55
The  ﬁrst  anti-adhesion  agent  that  proved  to  be  effec-
tive  in  the  treatment  of  IBD  was  natalizumab.  Natalizumab
is  an  anti-4-integrin  IgG4  non-gut-selective  antibody,  also
used  for  treating  multiple  sclerosis,  which  binds  to  41 and
47 integrins,  inhibiting  T-lymphocyte  adhesion  to  vascular
cell  adhesion  molecule-1  (VCAM-1)  and  mucosal  addressin
cell  adhesion  molecule-1  (MAdCAM-1).56,57 The  initial  enthu-
siasm  surrounding  its  success  was  halted  by  reports  of  the
aggressive  progressive  multifocal  leukoencephalopathy.58,59
Nevertheless,  this  agent  provided  proof  of  concept  and
paved  the  way  for  the  development  of  new  anti-adhesion
agents,  such  as  vedolizumab  (VDZ).1 VDZ  is  a  humanised
anti-47 integrin-IgG1  monoclonal  antibody  that  binds  to
MAdCAM-1.  Unlike  natalizumab,  VDZ  is  gut  speciﬁc,  provid-
ing  gut-selective  immunosuppression  with  similar  efﬁcacy,
with  a  lower  risk  of  systemic  infection.60 A  recent  study
using  the  anti-MAdCAM-1  antibody  showed  that  treatment
with  this  drug  does  not  affect  the  populations  of  CD4  and
CD8  lymphocytes  in  the  cerebrospinal  ﬂuid.61
The  results  of  the  phase  III,  randomized,  placebo-
controlled  trials  (RCT)  on  the  induction  and  maintenance  of
VDZ  in  UC  and  CD  (the  GEMINI  I  and  II  studies)  have  recently
been  published.62,63 In  the  UC  induction  study,62 374  patients
were  randomized  to  VDZ  at  a  dose  of  300  mg  or  placebo  at
week  0  and  week  2.  During  induction,  at  week  6,  47.1%  of
the  patients  on  VDZ  versus  25.5%  of  the  patients  on  placebo
achieved  clinical  response  (p  <  0.001).  Rates  of  mucosal
healing  (Mayo  score  0  or  1)  were  40.9%  for  VDZ  and  24.8%  for
placebo  (p  =  0.001).  A  second  cohort  of  521  patients  received
open-label  VDZ  at  weeks  0  and  2,  with  disease  evaluation  at
week  6.  Responders  from  both  cohorts  were  then  random-
ized  to  receive  drug  every  4  or  8  weeks  or  placebo.  A  total
of  41.8%  and  44.8%  maintained  remission  when  receiving
J
u
w
a107
edication  every  8  weeks  and  every  4  weeks,  respectively;
atients  on  placebo  had  maintenance  of  remission  at  a
ate  of  15.9%  (p  <  0.001  for  the  two  VDZ  groups,  respec-
ively,  vs.  placebo).62 Adverse  events  were  similar  in  both
roups.62
In  the  CD  induction  study,63 368  patients  were  random-
zed  to  300  mg  of  VDZ  or  placebo  at  weeks  0  and  2.  A
econd  cohort  of  747  patients  received  open-label  VDZ.  All
atients  were  followed  through  6  weeks.  Patients  on  VDZ
ad  a statistically  signiﬁcant  difference  in  clinical  remis-
ion  of  14.5  versus  6.8%  in  placebo  (p  =  0.02)  at  week  6,  but
o  difference  in  CDAI-100  response  or  reduction  in  mean  C-
eactive  protein  (CRP)  levels  at  week  6.63 Patients  from  both
ohorts  with  a  clinical  response  at  week  6  (461  patients)
ntered  the  maintenance  trial  and  were  randomized  to
eceive  VDZ  every  8  weeks,  or  every  4  weeks,  or  placebo
or  up  to  52  weeks.  In  the  VDZ  groups,  39%  and  36.4%  of
hose  assigned  to  VDZ  every  8  and  4  weeks,  respectively,
ere  in  clinical  remission  at  week  52,  as  compared  with
1.6%  assigned  to  placebo  (p  <  0.001  and  p  =  0.004  for  the
wo  VDZ  groups,  respectively,  vs.  placebo).  There  was  also
tatistical  signiﬁcance  in  CDAI-100  response,  and  steroid-
ree  remission  at  week  52  for  both  VDZ  groups  versus  placebo
p  <  0.001  and  0.004,  respectively).  Patients  with  prior  anti-
NF exposure  had  lower  clinical  response  and  remission
ates  at  week  6  and  week  52.63 In  the  CD  studies,  VDZ
as  associated  with  higher  degree  of  adverse  events  than
lacebo.
Based  on  these  studies,  VDZ  has  received  approval  for
arketing  in  CD  and  UC  for  patients  not  responding  to  one
r  more  standard  therapies  (corticosteroids,  immunomodu-
ators,  or  tumour  necrosis  factor  blocker  medications)  and
s  expected  to  arrive  in  the  clinical  practice  very  soon.  How
ill  VDZ  be  positioned  in  the  treatment  of  IBD?  So  far  no
ead-to-head  trials  are  available  comparing  anti-TNF  to
DZ.  For  CD  patients  it  is  apparent  from  the  RCT,  that  VDZ  is
ot  a  good  induction  drug,  because  it  may  require  a  longer
nduction  period  to  achieve  a  clinical  response.  Based  on  the
ivotal  trials,  it  will  probably  be  reserved  for  CD  patients
ith  moderate  to  severe  luminal  disease  not  responding  or
oosing  response  to  anti-TNF  agents.  Its  use  in  perianal  ﬁs-
ulising  disease  and  as  induction  ﬁrst-line  agent  will  require
urther  studies.
In UC,  a  meta-analysis  including  7  double-blind  placebo-
ontrolled  trials,  with  a  total  of  1502  patients  (720  given
lacebo),  showed  that  in  patients  with  moderate  to  severe
ctive  UC  naive  to  biological  therapy,  VDZ  has  similar  efﬁ-
acy  to  the  anti-TNF  antibodies  inﬂiximab,  adalimumab,
nd  golimumab  for  induction  of  response  and  remission  and
or  maintenance  of  response  and  remission.64 This  has  how-
ver  never  been  tested  in  real  life.  Likely  VDZ  will  be
eserved  for  the  treatment  of  ulcerative  colitis  patients  who
ail  one  anti-TNF,  given  its  success  in  this  population  of
atients  and  the  low  efﬁcacy  of  a  second  anti-TNF  agent
o  induce  a  clinical  response  in  this  setting.65
Many  more  promising  treatments  are  expected  to  arrive
n  the  next  years.  Etrolizumab,  which  is  also  an  anti-integrin,
s  currently  undergoing  phase  III  trials.  Tofacitinib,  an  oral
AK  inhibitor,  ustekinumab,  and  anti-IL12/IL23  are  also
ndergoing  clinical  trials.  Hopefully  some  of  these  new  drugs
ill  reach  the  clinic  and  become  part  of  the  therapeutic
rsenal  in  IBD.
1 C.  Palmela  et  al.
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de-escalation  criteria  are  not  yet  deﬁned.  De-escalation
strategies  may  include  discontinuation  of  the  immunosup-
pressant  (IS),  withdrawal  of  the  anti-TNF,  or  reducing  the
dose  of  one  or  both  drugs.80
A  randomized,  controlled  study  evaluated  the  impact  of
IS  discontinuation  in  CD  patients  receiving  combination  ther-
apy  with  IFX  and  in  remission  for  at  least  six  months.81 The
authors  found  that  although  patients  who  discontinued  IS
had  higher  C-reactive  protein  levels  and  lower  IFX  trough
levels,  there  were  similar  proportions  of  patients  needing
a  change  in  IFX  regimen  over  24  months  in  the  two  groups
(60%  and  55%  in  those  who  continued  and  interrupted  IS,
respectively).81
The  STORI  trial  from  the  GETAID  evaluated  the  impact
of  IFX  discontinuation  in  115  CD  patients  treated  with  IFX
plus  IS  for  more  than  one  year  and  with  steroid-free  remis-
sion  for  more  than  six  months.16 The  authors  found  relapse
rates  of  44%  and  52%  over  1  year  and  2  years  after  IFX
discontinuation,  respectively.16 In  a  multivariable  analy-
sis,  risk  factors  for  relapse  included  male  gender,  absence
of  surgical  resection,  leucocyte  counts  >  6.0  ×  109 L−1,  lev-
els  of  haemoglobin  ≤  145  g/L,  C-reactive  protein  ≥  5.0  mg/l,
faecal  calprotectin  ≥  300  g/g  and  absence  of  mucosal  heal-
ing  (CDEIS  >  0).16 Re-treatment  with  IFX  was  found  to  be
effective  and  well  tolerated  in  88%  of  patients  who  had
relapsed.16 No  prospective  data  in  UC  are  available  so
far.
Therefore,  in  patients  receiving  combination  therapy,
relapse  rate  after  IS  withdrawal  seems  lower  than  after  anti-
TNF  discontinuation,  therefore  the  former  is  considered
preferable  by  some  authors.79
A  step-down  approach  based  on  IS  or  anti-TNF  dose
reduction  according  to  disease  activity  has  been  studied  in
rheumatology  with  conﬂicting  results.82,83 Prospective  stud-
ies  in  IBD  are  needed  to  assess  the  beneﬁt  of  this  approach.
Finally,  complete  drug  withdrawal  would  be  the  ulti-
mate  goal  of  therapy  de-escalation  in  IBD.  However,  to
date,  treatment  discontinuation  in  patients  receiving
monotherapy  (with  either  IS  or  anti-TNF)  is  not  universally
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hat  we currently have
oss  of  response  (LOR)  is  an  important  issue  of  anti-TNF
herapy.66 Empiric  escalation  of  the  drug  either  by  increas-
ng  the  dose  or  shortening  the  interval  has  been  used  in
he  past  to  manage  loss  of  response  but  it  is  increasingly
eing  replaced  by  therapeutic  drug  monitoring  (TDM).  In  a
igniﬁcant  number  of  patients,  loss  of  response  is  mediated
hrough  formation  of  anti-drug  antibodies  (ADA).67 Sched-
led  anti-TNF  administration,  rather  than  episodic,  as  well
s  association  with  an  immunosuppressive  agent,  are  the
ain  strategies  to  reduce  ADA  formation.50
Commercially  available  assays  for  measuring  drug
etabolites  and  anti-drug  antibodies  (ADA)  for  inﬂiximab
IFX)  and  adalimumab  are  now  available  and  may  be  help-
ul  in  guiding  treatment  strategies  in  a  more  customized,
conomic  and  rational  way.68,69
Among  the  risk  factors  for  LOR,  immunogenicity  is  by
ar  the  most  important.  Despite  the  well  known  association
etween  ADA  formation,  lower  trough  levels  and  LOR,  only
ecently  has  the  kinetics  of  anti-drug  antibody  formation
een  described.70 In  this  study  by  Ungar  et  al,  among  125
atients  (98  CD,  27  UC)  treated  with  IFX,  sera  were  col-
ected  before  each  infusion  and  analyzed  for  ADA  and  IFX
rough  levels.  Around  46%  of  patients  developed  ADA,  and
0%  did  so  in  the  ﬁrst  12  months  of  therapy.  The  formation  of
DA  heralded  LOR  in  54%  of  patients  with  a  median  delay  of
 months.  Interestingly,  the  median  time  to  ADA  formation
as  1.5  months  (range  0.5--31  months),  meaning  that  75%  of
atients  by  week  22  of  treatment  had  developed  ADA.
Based  on  ADA  and  trough  levels  most  authorities  recom-
end  the  following  approach  to  patients  presenting  with
OR71:  (1)  patients  with  low  drug  levels  should  have  dose
ntensiﬁcation,  (2)  patients  with  high  concentrations  of  ADA
hould  switch  to  other  anti-TNF  molecule,  and  (3)  patients
ho  present  a  therapeutic  drug  concentration  without  ADA
hould  discontinue  anti-TNF  therapy  and  switch  to  another
lass  of  medications  or  consider  surgical  options,  after
ctive  disease  is  objectively  conﬁrmed.  We  must  bear  in
ind  some  important  aspects  of  this  algorithm.  In  ﬁrst  place
his  strategy  is  mainly  based  on  results  obtained  with  the
LISA  methodology,  which  is  limited  by  the  inability  to  mea-
ure  ADA  in  the  presence  of  circulating  drug.72 Secondly,  the
ptimal  drug  level  associated  with  clinical  response  is  still
 matter  of  debate,  as  detection  assays  may  vary  between
entres.  Nevertheless  trough  levels  for  IFX  of  3--7  g/mL73
nd  5--10  g/mL74 have  recently  been  suggested  as  a  target
or  maintenance  therapy  for  both  UC  and  CD,  respectively.75
or  adalimumab  5.85  g/mL  has  been  suggested  as  an  ade-
uate  trough  level.76 Finally,  this  algorithm  may  not  be
pplicable  to  almost  one-third  of  patients  with  results  out-
ide  the  deﬁned  cut-off  values.77
. Therapy de-escalation
f  a  patient  reaches  sustained  remission,  there  is  an
pportunity  for  treatment  de-escalation.  De-escalation
trategies  are  increasingly  being  considered  in  clinical
ractice  because  of  safety  concerns  (opportunistic  infec-
ions  and  cancer78)  and  economic  issues.79 However,  proper
Figure  1  New  trends  in  IBD:  (1)  utilization  of  prognostic  fac-
tors at  diagnosis;  (2)  the  use  of  a  ‘‘treat-to-target’’  strategy
and new  endpoints  in  patient  management;  and  (3)  new  drugs,
therapeutic  drug  monitoring  and  therapy  de-escalation.
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recommended  because  of  a  high  clinical  relapse  rate
(30--60%  at  12  months  after  IS  withdrawal  in  IBD  patients
under  IS  alone).79
In  conclusion,  de-escalation  treatment  strategies  should
be  mainly  considered  in  highly  selected  CD  patients  with  a
high  risk  of  severe  adverse  events  and  low  risk  of  relapse
after  treatment  withdrawal  (deep  remission:  including
clinical  remission,  biomarker  normalization  and  complete
mucosal  healing).  In  the  future,  the  ultimate  target  in  IBD
will  probably  be  ‘‘complete’’  remission,  including  also  his-
tological  and  molecular  healing.  Nonetheless  the  prognostic
value  of  histological  remission  as  a  treatment  target  in  IBD
needs  to  be  conﬁrmed  and  validated  histological  scores  are
needed.84
8. Conclusions
New  trends  are  emerging  in  IBD  (Fig.  1),  with  the  hope
of  changing  natural  history  of  disease.  Among  the  new
drugs  expected  to  arrive  in  the  next  years,  vedolizumab,
etrolizumab,  ustekinumab  and  tofacitinib  appear  to  be  the
most  promising.
A  new  paradigm  moving  towards  disease  modiﬁcation  in
CD  is  emerging  which  includes  early  intensive  (if  necessary)
treatment  and  tight  disease  control.  Early  treatment  with
immunosuppressants  and/or  biologics  in  patients  with  poor
prognostic  factors  should  be  considered.
A  ‘‘treat-to-target’’  strategy,  based  on  frequent  assess-
ment  of  disease  activity  and  subsequent  adjustment  of
treatment  accordingly,  may  modify  the  natural  course  of
IBD.  The  use  of  monitoring  tools  such  as  endoscopy,  cross-
sectional  imaging  and  biomarkers  has  not  been  prospectively
validated  and  remains  empirical.  Mucosal  healing  appears  to
be  an  important  treatment  endpoint  but  there  is  a  need  for
a  validated  universal  deﬁnition  and  to  use  a  standardized
validated  endoscopic  score  both  in  UC  and  CD.  The  use  of
non-invasive  inﬂammatory  biomarkers  as  well  as  blood  drug
levels  may  improve  the  efﬁcacy  of  therapy  monitoring.  Fur-
ther  prospective  studies  to  assess  beneﬁts  and  potential  risks
of  a  ‘‘treat-to-target’’  approach  on  long-term  outcomes  in
IBD  are  needed.
Additionally,  the  increased  use  of  immunomodulators,
administered  earlier  and  for  longer  periods,  raised  consid-
eration  about  treatment  de-escalation  and  safety  of  chronic
immunosuppression.  Predictors  for  relapse  following  ther-
apy  discontinuation  in  IBD  are  needed.
In  conclusion,  new  endpoints  are  arising  and  new  strate-
gies  aiming  at  the  sustained  suppression  of  inﬂammation,
and  involving  disease  activity  monitoring  in  a  ‘‘treat-to-
target’’  approach  are  becoming  increasingly  incorporated
in  the  daily  clinical  practice  of  treating  IBD.
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